Routine Prostate Cancer Screening Doesn't Reduce Risk of Death

PHOTO: An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer.

Routine screening for prostate cancer does not lower the risk of dying from the disease, according to new study results, reigniting the controversy over the benefits of annual testing.

In a follow-up to previously reported data, researchers led by Dr. Gerald Andriole, chief of urologic surgery at Washington University School of Medicine in St. Lous, found that men who underwent yearly screening for prostate cancer, which included a digital rectal examination and a blood test for prostate-specific antigen (PSA) levels, had the same chance of dying from prostate cancer as men who were tested less often.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial followed nearly 77,000 men ages 55 to 74 for 13 years. Men in the intensive screening group had a PSA test every year for six years and a rectal examination annually for four years.

The researchers first reported there was no difference in mortality between the two groups after following the men for 7 to 10 years, but after criticism that the men should be followed longer since prostate cancer is a slowly progressing disease, they extended the follow-up to 13 years and got the same result.

"The finding is along the lines that routine mass screening of men is probably not very beneficial as far as reducing the chance of dying from prostate cancer," Andriole said. But he also stressed that some men -- those who are young and healthy, have a long life expectancy or have a strong family history of prostate cancer -- will benefit. African-American men, who are twice as likely to die from prostate cancer as Caucasian men, should also be regularly screened.

The value of annual PSA screening has been hotly debated by the medical community. Some say regular testing has saved many lives; others argue proof of its benefits just isn't there. In December, the U.S. Preventive Services Task Force issued draft recommendations saying the available data are unclear to support routine screening in men younger than 75. They also recommend against screening in men 75 and older.

Experts told that the latest findings from the PLCO don't lend much to either side of the argument because the study contained numerous flaws. One of them, they explained, is because although one group was screened annually, more than half of the men in the other group did get occasional screening as part of their usual medical care, making it difficult to figure out the true effect of screening.

"There was also a large study in Europe that had significant flaws as well, and that study showed a mortality benefit, so the two largest studies had these similar flaws and came to different conclusions," said Dr. Durado Brooks, director of prostate and colorectal cancers for the American Cancer Society. "There are no clear answers to take away from this."

Even medical organizations have different recommendations on prostate cancer screening. The American Urological Association recommends that all men 40 and older be offered a screening test if they want it, but the American Cancer Society says while there may be some benefit to screening, it can also be harmful, so men should make an informed decision with their doctor based on personal beliefs and whether they are at risk.

  • 1
  • |
  • 2
Join the Discussion
blog comments powered by Disqus
You Might Also Like...